Friedman Gregory K, Pressey Joseph G, Reddy Alyssa T, Markert James M, Gillespie G Yancey
Department of Pediatrics, Children's Hospital of Alabama, University of Alabama at Birmingham, USA.
Mol Ther. 2009 Jul;17(7):1125-35. doi: 10.1038/mt.2009.73. Epub 2009 Apr 14.
Despite improving survival rates for children with cancer, a subset of patients exist with disease resistant to traditional therapies such as surgery, chemotherapy, and radiation. These patients require newer, targeted treatments used alone or in combination with more traditional approaches. Oncolytic herpes simplex virus (HSV) is one of these newer therapies that offer promise for several difficult to treat pediatric malignancies. The potential benefit of HSV therapy in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas is reviewed along with the many challenges that need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the beside in the pediatric population.
尽管儿童癌症患者的生存率有所提高，但仍有一部分患者的疾病对手术、化疗和放疗等传统疗法具有抗性。这些患者需要更新的靶向治疗，可单独使用或与更传统的方法联合使用。溶瘤单纯疱疹病毒（HSV）就是这些新疗法之一，有望用于治疗几种难治的儿科恶性肿瘤。本文综述了HSV疗法在包括脑肿瘤、神经母细胞瘤和肉瘤在内的儿科实体瘤中的潜在益处，以及在将溶瘤HSV疗法从实验室应用于儿科患者床边之前需要解决的诸多挑战。
